Results 231 to 240 of about 41,337 (280)
Inhibitory HLA-C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. [PDF]
EJHaemShivarov V +3 more
europepmc +1 more source
Bleeding, Thrombosis, and Anticoagulation in Myeloproliferative Neoplasms (MPN): Analysis From the German SAL-MPN-Registry [PDF]
Journal of Hematology and Oncology, 2016 Background: Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboembolism and major bleeding. Due to the
Steffen Koschmieder, E Jost, H Serve
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2022
Molecular laboratory investigations for myeloproliferative neoplasm (MPN) can ideally be divided into two distincts groups, those for the detection of the BCR-ABL rearrangement (suspect of chronic myeloid leukemia) and those for the variants determination of the driver genes of the negative Philadelphia forms (MPN Ph neg).
Alice, Moncada, Alessandro, Pancrazzi
openaire +2 more sources
Molecular laboratory investigations for myeloproliferative neoplasm (MPN) can ideally be divided into two distincts groups, those for the detection of the BCR-ABL rearrangement (suspect of chronic myeloid leukemia) and those for the variants determination of the driver genes of the negative Philadelphia forms (MPN Ph neg).
Alice, Moncada, Alessandro, Pancrazzi
openaire +2 more sources
Mutational Landscape of Blast Phase Myeloproliferative Neoplasms (MPN-BP) and Antecedent MPN
International Review of Cell and Molecular Biology, 2022Myeloproliferative neoplasms (MPN) have an inherent tendency to evolve to the blast phase (BP), characterized by ≥20% myeloblasts in the blood or bone marrow. MPN-BP portends a dismal prognosis and currently, effective treatment modalities are scarce, except for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in selected patients ...
Helen T Chifotides +2 more
exaly +3 more sources
Management of Myeloproliferative Neoplasms (MPNs)
Journal of Oncology Pharmacy Practice, 2022Purpose To provide up to date guidance, practice recommendations and highlight barriers to medication adherence in the long-term management of chronic myeloproliferative neoplasms (MPNs). Aim Current drug therapy for MPN is not ...
Zubeir Nurgat, Myer Lawrence
openaire +2 more sources
Current Hematologic Malignancy Reports, 2017
Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been ...
Tsewang, Tashi +2 more
openaire +2 more sources
Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been ...
Tsewang, Tashi +2 more
openaire +2 more sources
Approach to MPN Symptom Assessment
Current Hematologic Malignancy Reports, 2017 Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden.Significant heterogeneity exists ...
Ruben Mesa, Holly L Geyer
exaly +4 more sources